[Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent]. Ogren SO, Hall H, Köhler C, Magnusson O, Florvall L. Arzneimittelforschung. 1985;35(8):1227-31. PMID: 2866774
[Some pharmacological aspects of neuroleptics (author's transl)]. Niemegeers CJ. Encephale. 1981;7(3):215-24. PMID: 6116591
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. Meltzer HY, Matsubara S, Lee JC. J Pharmacol Exp Ther. 1989 Oct;251(1):238-46. PMID: 2571717
[Dopamine D4-receptor variants, schizophrenia and clozapine therapy]. Ewald HL, Mors NP, Rosenberg R. Ugeskr Laeger. 1996 Jun 17;158(25):3601-3. PMID: 8693618
Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes. Moran-Gates T, Massari C, Graulich A, Liégeois JF, Tarazi FI. J Neurosci Res. 2006 Aug 15;84(3):675-82. doi: 10.1002/jnr.20972. PMID: 16810690
Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13. PMID: 7562537
Dopamine receptors and the dopamine hypothesis of schizophrenia. Seeman P. Synapse. 1987;1(2):133-52. doi: 10.1002/syn.890010203. PMID: 2905529
